Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®)
Reference No. 3414
Publication date:
04/12/2018
Appraisal information
bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) 50 mg/200 mg/25 mg film-coated tablet
Company:
Gilead Sciences Ltd
BNF category:
Infections
NMG meeting date:
10/10/2018
AWMSG meeting date:
14/11/2018
Submission Type:
Full Submission
Status:
Recommended with restrictions
Advice No:
1918
Ratification by Welsh Government:
03/12/2018
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) is recommended as an option for restricted use within NHS Wales. Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) is licensed for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) is restricted for use to patients who are either unsuitable for or unable to tolerate dolutegravir/abacavir/lamivudine (Triumeq®). Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) is not recommended for use within NHS Wales outside of this subpopulation. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
AWMSG Secretariat Appraisal Report (ASAR)
Download
bictegravir (Biktarvy) 3414 ASAR
Final Appraisal Recommendation (FAR)
Download
bictegravir (Biktarvy) 3414 FAR